Onconetix (ONCO) FCF Margin (2024 - 2026)
Onconetix (ONCO) posted quarterly FCF Margin of 3513.74% for Q4 2025, down 338431.0% year-over-year from N/an in Q4 2024, and down 234.47% quarter-over-quarter from 1050.56% in Q3 2025.
Onconetix (ONCO) FCF Margin (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported FCF Margin for 2 consecutive years, with 3513.74% the latest figure, recorded in Q4 2025.
- In Q4 2025, FCF Margin fell 338431.0% year-over-year to 3513.74%; the TTM figure through Mar 2026 stood at 1966.47% (down 158630.0% YoY), while the FY2025 annual figure was 1616.67%, down 119972.0% from the prior year.
- FCF Margin eased to 3513.74% in Q4 2025 per ONCO's latest filing, from 1050.56% in the prior quarter.
- Across five years, FCF Margin topped out at 129.43% in Q4 2024 and bottomed at 3513.74% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 70.82% |
| 10 | Onconetix | 1.45 Mn | -4.50 Mn | 4,303.00 | -11,203.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,203.66% |
| Mar 31, 2026 | -9,887.13% |
| Dec 31, 2025 | -3,513.74% |
| Sep 30, 2025 | -1,050.56% |
| Jun 30, 2025 | -1,324.30% |
| Mar 31, 2025 | -1,999.68% |
| Dec 31, 2024 | -129.43% |
| Sep 30, 2024 | -287.22% |
| Jun 30, 2024 | -456.44% |
| Mar 31, 2024 | -747.63% |